Switch theme
Sign up to access all valuation multiples
Stratec SE designs and manufactures automated analyzer systems for laboratory data management and solutions for molecular diagnostic sample preparation and stabilization. Its business segments are Instrumentation, Diatron and Smart Consumables. Its Instrumentation segment is engaged in designing and manufacturing automated analyzer systems for clinical diagnostics and biotechnology customers. The Diatron segment comprises the business with systems, system components, consumables, and tests in the low throughput hematology and clinical chemistry segment. Its Smart Consumables segment is engaged in developing and selling scientific materials, such as nucleic acid purification. The company generates maximum revenue from the Instrumentation segment.
1979
1.5K+
LTM Revenue $298M
LTM EBITDA $51.3M
$441M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Stratec has a last 12-month revenue (LTM) of $298M and a last 12-month EBITDA of $51.3M.
In the most recent fiscal year, Stratec achieved revenue of $289M and an EBITDA of $53.2M.
Stratec expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Stratec valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $298M | XXX | $289M | XXX | XXX | XXX |
| Gross Profit | $88.9M | XXX | $85.8M | XXX | XXX | XXX |
| Gross Margin | 30% | XXX | 30% | XXX | XXX | XXX |
| EBITDA | $51.3M | XXX | $53.2M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 18% | XXX | XXX | XXX |
| EBIT | $31.2M | XXX | $31.7M | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $20.1M | XXX | $18.0M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 6% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $76.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Stratec's stock price is EUR 26 (or $29).
Stratec has current market cap of EUR 311M (or $350M), and EV of EUR 393M (or $441M).
See Stratec trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $441M | $350M | XXX | XXX | XXX | XXX | $2.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Stratec has market cap of $350M and EV of $441M.
Stratec's trades at 1.5x EV/Revenue multiple, and 8.3x EV/EBITDA.
Equity research analysts estimate Stratec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Stratec has a P/E ratio of 17.4x.
See valuation multiples for Stratec and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $350M | XXX | $350M | XXX | XXX | XXX |
| EV (current) | $441M | XXX | $441M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 8.6x | XXX | 8.3x | XXX | XXX | XXX |
| EV/EBIT | 14.1x | XXX | 13.9x | XXX | XXX | XXX |
| EV/Gross Profit | 5.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 17.4x | XXX | 19.4x | XXX | XXX | XXX |
| EV/FCF | 14.3x | XXX | 12.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialStratec's last 12 month revenue growth is 7%
Stratec's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $36K for the same period.
Stratec's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Stratec's rule of X is 34% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Stratec and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | 22% | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $36K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Stratec acquired XXX companies to date.
Last acquisition by Stratec was XXXXXXXX, XXXXX XXXXX XXXXXX . Stratec acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Stratec founded? | Stratec was founded in 1979. |
| Where is Stratec headquartered? | Stratec is headquartered in Germany. |
| How many employees does Stratec have? | As of today, Stratec has 1.5K+ employees. |
| Is Stratec publicy listed? | Yes, Stratec is a public company listed on ETR. |
| What is the stock symbol of Stratec? | Stratec trades under SBS ticker. |
| When did Stratec go public? | Stratec went public in 1998. |
| Who are competitors of Stratec? | Similar companies to Stratec include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Stratec? | Stratec's current market cap is $350M |
| What is the current revenue of Stratec? | Stratec's last 12 months revenue is $298M. |
| What is the current revenue growth of Stratec? | Stratec revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Stratec? | Current revenue multiple of Stratec is 1.5x. |
| Is Stratec profitable? | Yes, Stratec is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Stratec? | Stratec's last 12 months EBITDA is $51.3M. |
| What is Stratec's EBITDA margin? | Stratec's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Stratec? | Current EBITDA multiple of Stratec is 8.6x. |
| What is the current FCF of Stratec? | Stratec's last 12 months FCF is $30.9M. |
| What is Stratec's FCF margin? | Stratec's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Stratec? | Current FCF multiple of Stratec is 14.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
